Cite
Haas DW, Mngqibisa R, Francis J, et al. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics. 2022;32(1):24-30doi: 10.1097/FPC.0000000000000448.
Haas, D. W., Mngqibisa, R., Francis, J., McIlleron, H., Robinson, J. A., Kendall, M. A., Baker, P., Mawlana, S., Badal-Faesen, S., Angira, F., Omoz-Oarhe, A., Samaneka, W. P., Denti, P., Cohn, S. E. (2022). Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and genomics, 32(1), 24-30. https://doi.org/10.1097/FPC.0000000000000448
Haas, David W, et al. "Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis." Pharmacogenetics and genomics vol. 32,1 (2022): 24-30. doi: https://doi.org/10.1097/FPC.0000000000000448
Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics. 2022 Jan 01;32(1):24-30. doi: 10.1097/FPC.0000000000000448. PMID: 34369424; PMCID: PMC8578190.
Copy
Download .nbib